Cellular Proliferation Imaging With 18 F-FMAU PET/CT as Adjunct to mpMRI in Image-Guided Biopsy of Suspected Prostate Cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 39924745.
- Also identified by DOI 10.1097/RLU.0000000000005702 and PMC identifier 12052491.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We evaluated the potential diagnostic utility of PET with the cellular proliferation biomarker, 2'-deoxyl-2'-[ 18 F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil ( 18 F-FMAU), as an adjunct to multiparametric MRI (mpMRI), in localization of sites for image-guided biopsy in men with suspected prostate cancer. Seventeen men with clinically suspected prostate cancer underwent standard mpMRI and investigational PET/CT with 18 F-FMAU. Tissue samples obtained from 22 image-guided biopsies were examined histologically. There were 11 benign, 6 ISUP grade 1, and 5 ISUP grade 2 tumors. The sensitivity for detection of ISUP 1 and ISUP 2 prostate cancer was 16.7% and 100% for mpMRI, and 50% and 60% for 18 F-FMAU PET/CT, respectively. 18 F-FMAU PET/CT may be a useful adjunct to mpMRI in image-guided prostate biopsy.
Medical subject headings
- Prostatic Neoplasms
- Positron Emission Tomography Computed Tomography
- Image-Guided Biopsy
- Multiparametric Magnetic Resonance Imaging
- Arabinofuranosyluracil